BR112021021904A2 - Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível - Google Patents
Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerívelInfo
- Publication number
- BR112021021904A2 BR112021021904A2 BR112021021904A BR112021021904A BR112021021904A2 BR 112021021904 A2 BR112021021904 A2 BR 112021021904A2 BR 112021021904 A BR112021021904 A BR 112021021904A BR 112021021904 A BR112021021904 A BR 112021021904A BR 112021021904 A2 BR112021021904 A2 BR 112021021904A2
- Authority
- BR
- Brazil
- Prior art keywords
- clotting
- cfs
- capsule
- delivery
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3295—Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
- A61M2005/14284—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation with needle insertion means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
- A61M2205/6072—Bar codes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível. modalidades fornecem dispositivos, preparações e métodos para a liberação de agentes terapêuticos (tas) como, por exemplo, fatores de coagulação (cfs), por exemplo, fator viii (fviii), incluindo peguilado e outras formas de fviii estabilizado, dentro do trato gi. muitas modalidades fornecem um dispositivo ingerível, por exemplo, uma cápsula, para a liberação de tas na parede intestinal (iw).modalidades também fornecem preparações de ta configuradas para estarem contidas dentro da cápsula, avançadas da cápsula na iw e/ou tecido circundante (st) e se degradam para liberar o ta na corrente sanguínea para produzir um efeito terapêutico (por exemplo, coagulação aumentada). a preparação pode estar acoplada operativamente a meios de liberação que possuem uma primeira configuração na qual a preparação está contida na cápsula e uma segunda configuração na qual a preparação é avançada para fora da cápsula dentro da iw ou st (por exemplo, da cavidade peritoneal). modalidades são particularmente úteis para a liberação de cfs para o tratamento de distúrbios da coagulação (por exemplo, hemofilia), em que esses cfs são pobremente absorvidos e/ou degradados dentro do trato gi.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962843221P | 2019-05-03 | 2019-05-03 | |
US201962845209P | 2019-05-08 | 2019-05-08 | |
PCT/US2020/031197 WO2020227162A1 (en) | 2019-05-03 | 2020-05-01 | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021021904A2 true BR112021021904A2 (pt) | 2022-02-22 |
Family
ID=73050863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021904A BR112021021904A2 (pt) | 2019-05-03 | 2020-05-01 | Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220118056A1 (pt) |
EP (1) | EP3962516A4 (pt) |
JP (1) | JP2022530615A (pt) |
KR (1) | KR20220004148A (pt) |
CN (1) | CN114007638A (pt) |
AU (1) | AU2020270420A1 (pt) |
BR (1) | BR112021021904A2 (pt) |
CA (1) | CA3137539A1 (pt) |
MX (1) | MX2021013310A (pt) |
WO (1) | WO2020227162A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10603275B2 (en) | 2017-11-07 | 2020-03-31 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
WO2022182712A1 (en) * | 2021-02-24 | 2022-09-01 | Rani Therapeutics, Llc | Treatments for hemophilia a |
JP2024513983A (ja) * | 2021-04-13 | 2024-03-27 | グリフォルス・ワールドワイド・オペレーションズ・リミテッド | 第viii因子または第viii因子/フォン・ヴィレブランド因子複合体を含む液体組成物 |
CN115300774B (zh) * | 2022-08-27 | 2024-01-30 | 深圳市资福医疗技术有限公司 | 一种药剂递送装置、释药方法及应用其的释药胶囊 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9149617B2 (en) * | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
TWI687226B (zh) * | 2011-07-08 | 2020-03-11 | 美商百歐維拉提夫治療公司 | 因子viii嵌合及雜交多肽,及其使用方法 |
US20140019297A1 (en) * | 2012-07-10 | 2014-01-16 | Bootic, Inc. | Electronic Commerce System Incorporating Shopping Baskets |
US10689460B2 (en) * | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US11548940B2 (en) * | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
EP3288543A4 (en) * | 2015-05-01 | 2018-11-14 | Incube Labs, LLC | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
JP2018526403A (ja) * | 2015-09-08 | 2018-09-13 | インキューブ ラブズ, エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのpcsk9抗体製剤 |
KR102175878B1 (ko) * | 2016-06-24 | 2020-11-06 | 재단법인 목암생명과학연구소 | Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도 |
US10603275B2 (en) * | 2017-11-07 | 2020-03-31 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
-
2020
- 2020-05-01 EP EP20801591.7A patent/EP3962516A4/en active Pending
- 2020-05-01 CN CN202080047333.3A patent/CN114007638A/zh active Pending
- 2020-05-01 KR KR1020217038935A patent/KR20220004148A/ko unknown
- 2020-05-01 CA CA3137539A patent/CA3137539A1/en active Pending
- 2020-05-01 JP JP2021562389A patent/JP2022530615A/ja active Pending
- 2020-05-01 AU AU2020270420A patent/AU2020270420A1/en active Pending
- 2020-05-01 MX MX2021013310A patent/MX2021013310A/es unknown
- 2020-05-01 BR BR112021021904A patent/BR112021021904A2/pt unknown
- 2020-05-01 WO PCT/US2020/031197 patent/WO2020227162A1/en unknown
-
2021
- 2021-10-29 US US17/515,284 patent/US20220118056A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220118056A1 (en) | 2022-04-21 |
KR20220004148A (ko) | 2022-01-11 |
WO2020227162A1 (en) | 2020-11-12 |
JP2022530615A (ja) | 2022-06-30 |
EP3962516A1 (en) | 2022-03-09 |
AU2020270420A1 (en) | 2021-11-18 |
CA3137539A1 (en) | 2020-10-20 |
CN114007638A (zh) | 2022-02-01 |
EP3962516A4 (en) | 2023-01-04 |
MX2021013310A (es) | 2022-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021021904A2 (pt) | Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível | |
BR112021017993A2 (pt) | Preparações de agente terapêutico e métodos para liberação de fármacos em um lúmen do trato intestinal com o uso de um dispositivo ingerível de liberação de fármacos | |
BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
BR112015004244A2 (pt) | composição médica oralmente administrada | |
BR112016029316A2 (pt) | composição farmacêutica para uso na prevenção e/ou tratamento de doença que se desenvolve ou progride como um resultado da diminuição ou deficiência da atividade do fator de coagulação sanguínea viii e/ou fator de coagulação sanguínea ativado viii | |
BR112014016085A8 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
BR112015021446A2 (pt) | métodos cirúrgicos empregando composições de peptídeo amfifílico purificado | |
BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
WO2011112229A3 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
BR112015022067A2 (pt) | método e aparato para a administração de droga a um sítio alvo | |
MX2021007904A (es) | Preparaciones de agente terapéutico para administración en un lumen del tracto intestinal utilizando un dispositivo de administración de fármaco tragable. | |
BR0008039A (pt) | Combinações de formoterol e um sal de tiotrópio | |
EA201101518A1 (ru) | Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии | |
BR112018003892A2 (pt) | ?composição farmacêutica e método para a redução da gordura? | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
JP2015524444A5 (pt) | ||
BR102013003570A8 (pt) | Composições de plasma rico em plaquetas | |
BR112022016100A2 (pt) | Composição farmacêutica compreendendo microgrânulos de liberação sustentada incluindo análogo de glp-1 ou sal farmaceuticamente aceitável do mesmo | |
UA102885C2 (ru) | Таблетка для орального введения, которая содержит тамсулозин и солифенацин | |
BR112013010829B1 (pt) | Omposição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
BRPI0607172A2 (pt) | método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos | |
BR112017022984A2 (pt) | dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente |